Entrada Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $55.0M | $23.5M | $-9.5M | $35.5M | $-25.9M | $-6.7M | $-24.6M | $-25.1M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $900.0K | $934.0K | $800.0K | $800.0K | $700.0K | $541.0K | $505.0K | $500.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $4.6M | $3.7M | $3.8M | $3.4M | $3.1M | $2.8M | $2.9M | $2.7M |
| Net Cash from Operating Activities | $39.8M | $-25.5M | $-4.0M | $-24.5M | $-35.1M | $203.4M | $-27.3M | $-27.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.0M | $838.0K | $976.0K | $1.4M | $1.5M | $1.7M | $708.0K | $810.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-24.4M | $26.1M | $19.0M | $-3.7M | $-113.3M | $-40.4M | $18.8M | $-10.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $101.4M | $206.0K | $690.0K | $368.0K | $443.0K | $19.5M | $358.0K | $60.0K |
| Net Change in Cash | $116.8M | $834.0K | $15.7M | $-27.9M | $-147.9M | $182.5M | $-8.2M | $-37.6M |
| Free Cash Flow | $38.8M | $-26.4M | $-5.0M | $-25.9M | $-36.6M | $201.7M | $-28.0M | $-28.3M |